前列腺切除术后前列腺床局部复发的挽救性立体定向再照射:一项回顾性多中心研究
这项多中心回顾性研究纳入117例根治性前列腺切除和放疗后前列腺床局部复发的患者,评估挽救性立体定向体部放疗(SBRT)的疗效与安全性。中位随访19.5个月,中位无进展生存期23.5个月(95%CI 17.6-33.2),3年≥2级晚期泌尿生殖或胃肠道毒性累积发生率为18%(95%CI 10-26)。作者认为该方案可提供令人鼓舞的控制和可接受的毒性,需进一步前瞻性研究。
要点
- 挽救性SBRT中位剂量35 Gy,中位无进展生存期23.5个月(95%CI 17.6-33.2)。
- 复发体积每增加10 cm³,无进展生存期风险比HR=1.46(95%CI 1.08-1.96;p=0.01)。
- 复发灶接触尿道膀胱吻合口与无进展生存期相关(HR=3.35;95%CI 1.38-8.16;p=0.008)。
核心结论
- 对前列腺床局部复发的挽救性SBRT可能提供令人鼓舞的控制和可接受的毒性,因此需要进一步的前瞻性研究。
研究设计与样本
- 多中心回顾性系列研究,纳入11个中心、三个国家的117例根治性前列腺切除和放疗后前列腺床局部复发并接受挽救性SBRT的患者。
- 采用Kaplan-Meier法估计无进展生存期(生化、临床或两者兼有),生化复发定义为前列腺特异性抗原最低点+0.2 ng/ml并经第二次升高确认。
- 采用Kalbfleisch-Prentice法估计晚期毒性累积发生率,将复发或死亡视为竞争事件。
主要发现
- 中位随访19.5个月,中位SBRT剂量35 Gy。
- 中位无进展生存期为23.5个月(95%CI 17.6-33.2)。
- 多变量模型中,复发体积与无进展生存期显著相关(每10 cm³的HR=1.46;95%CI 1.08-1.96;p=0.01)。
- 复发灶与尿道膀胱吻合口接触与无进展生存期显著相关(HR=3.35;95%CI 1.38-8.16;p=0.008)。
- 3年≥2级晚期泌尿生殖或胃肠道毒性累积发生率为18%(95%CI 10-26)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of local recurrence of prostate cancer (PCa) in the prostatic bed after radical prostatectomy (RP) and radiotherapy remains challenging. OBJECTIVE: To assess the efficacy and safety of salvage stereotactic body radiotherapy (SBRT) reirradiation in this setting and evaluate prognostic factors. DESIGN, SETTING, AND PARTICIPANTS: We conducted a large multicenter retrospective series that included 117 patients who were treated with salvage SBRT for local recurrence in the prostatic bed after RP and radiotherapy in 11 centers across three countries. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Progression-free survival (PFS; biochemical, clinical, or both) was estimated using the Kaplan-Meier method. Biochemical recurrence was defined as prostate-specific antigen nadir +0.2 ng/ml, confirmed by a second increasing measure. The cumulative incidence of late toxicities was estimated using the Kalbfleisch-Prentice method by considering recurrence or death as a competing event. RESULTS AND LIMITATIONS: The median follow-up was 19.5 mo. The median SBRT dose was 35 Gy. The median PFS was 23.5 mo (95% confidence interval [95% CI], 17.6-33.2). In the multivariable models, the volume of the recurrence and its contact with the urethrovesical anastomosis were significantly associated with PFS (hazard ratio [HR]/10 cm3 = 1.46; 95% CI, 1.08-1.96; p = 0.01 and HR = 3.35; 95% CI, 1.38-8.16; p = 0.008, respectively). The 3-yr cumulative incidence of grade ≥2 late GU or GI toxicity was 18% (95% CI, 10-26). In the multivariable analysis, a recurrence in contact with the urethrovesical anastomosis and D2% of the bladder were significantly associated with late toxicities of any grade (HR = 3.65; 95% CI, 1.61-8.24; p = 0.002 and HR/10 Gy = 1.88; 95% CI, 1.12-3.16; p = 0.02, respectively). CONCLUSIONS: Salvage SBRT for local recurrence in the prostate bed may offer encouraging control and acceptable toxicity. Therefore, further prospective studies are warranted. PATIENT SUMMARY: We found that salvage stereotactic body radiotherapy after surgery and radiotherapy allows for encouraging control and acceptable toxicity in locally relapsed prostate cancer.
引用
- Archer P, Marvaso G, Detti B, et al. Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study. Eur Urol Oncol. 2023. PMID: 37012102. doi:10.1016/j.euo.2023.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。